Abstract
In this report we investigated the immunopharmacological role of selective and nonselective phosphodiesterase (PDE) inhibition in regulating the inhibitory-κB (IκB-α)/nuclear factor-κB (NF-κB) signaling transduction pathway. In fetal alveolar type II epithelial cells, PDE blockade at the level of the diverging cAMP/cGMP pathways differentially regulated the phosphorylation and degradation of IκB-α, the major cytosolic inhibitor of NF-κB. Whereas selective inhibition of PDEs 1, 3, and 4, by the action of 8-methoxymethyl-3-isobutyl-1-methylxanthine, amrinone, and rolipram, respectively, exhibited a tendency to augment the translocation of NF-κB1 (p50), RelA (p65), RelB (p68), and c-Rel (p75), selective blockade of PDE 5, 6, and 9, by the action of 4-{[3′,4′-(methylenedioxy)benzyl]amino}-6-methoxyquinazoline and zaprinast, attenuated lipopolysaccharide-endotoxin (LPS)-mediated NF-κB translocation. Pentoxifylline, a nonspecific PDE inhibitor, reversed the excitatory effect of LPS on NF-κB subunit nuclear localization, in a dose-dependent manner. Furthermore, analysis of NF-κB activation under the same conditions revealed a biphasic effect mediated by LPS. PDEs 1, 3, and 4 inhibition was associated with up-regulating NF-κB transcriptional activity. In contrast, blockading the activity of PDEs 5, 6, and 9 negatively attenuated LPS-mediated NF-κB activation, similar to the effect of 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione (pentoxifylline). These results indicate that selective and nonselective interference with the control of the dynamic equilibrium of cyclic nucleotides via PDE isoenzyme regulation represents an immunoregulatory mechanism that requires the differential, biphasic targeting of the IκB-α/NF-κB pathway.
Although the transcription factor nuclear factor-κB (NF-κB) has been originally recognized in regulating gene expression in B-cell lymphocytes (Sen and Baltimore, 1986), subsequent investigations have demonstrated that it is one member of a ubiquitously expressed family of Rel-related transcription factors that serve as critical regulators of many genes, including those of proinflammatory cytokines (Siebenlist et al., 1994; Baldwin, 1996, 2001; Haddad et al., 2001b). The translocation and activation of NF-κB in response to various stimuli are sequentially organized at the molecular level. In its inactive state, the heterodimeric NF-κB, which is mainly composed of two subunits, p50 (NF-κB1) and p65 (RelA), is present in the cytoplasm associated with its inhibitory protein, IκB (Siebenlist et al., 1994; Baldwin, 1996). Upon stimulation, such as with cytokines and lipopolysaccharide-endotoxin (LPS), derived from the cell wall of Gram-negative bacteria, IκB-α, the major cytosolic inhibitor of NF-κB (Baldwin, 1996; Haddad et al., 2001b), undergoes phosphorylation on serine/threonine residues, ubiquitination, and subsequent proteolytic degradation, thereby unmasking the nuclear localization signal (NLS) on p65 and allowing nuclear translocation of the complex. This sequential propagation of signaling ultimately results in the release of NF-κB subunits from IκB-α inhibitor, allowing translocation and promotion of gene transcription.
Phosphodiesterases (PDEs), a family of isoenzymes involved in regulating the dynamic equilibrium of cyclic nucleotides (cAMP/cGMP) (Pagani et al., 1992; Bolger et al., 1993; Tsuboi et al., 1996; Ekholm et al., 1997; Perry and Higgs, 1998; Essayan, 1999), have been recently implicated in regulating the IκB-α/NF-κB signaling pathway and other transcription factors (Montminy, 1997). For instance, it was reported that the transcriptional activity of NF-κB was regulated by the IκB-associated catalytic subunit of protein kinase A (PKAc) in a cAMP-independent mechanism (Zhong et al., 1997). Furthermore, Wang et al. (1997) observed that c-Rel (p75), one of the members of theRel family, formed a selective target of pentoxifylline, a nonspecific PDE inhibitor, in mediating the inhibition of T-lymphocyte activation. In addition, pentoxifylline blockaded reactive oxygen species-mediated regulation of NF-κB independently of the phosphodiesterase inhibitory activity (Lee et al., 1997). Relatively recently, a correlation of note was observed between the suppression of proinflammatory cytokine production and the inhibition of NF-κB/NFAT signaling pathway mediated by PDE type 4 isozymes (Navarro et al., 1998). Moreover, Tomita et al. (1999) reported a novel role for dexamethasone and theophylline, another nonspecific inhibitor of PDE, in regulating NF-κB translocation/activation and cytokine expression. In addition, selective inhibition of PDE 3 attenuated the activation of NF-κB and subsequently blockaded the downstream cytokine signaling pathway (Matsumori et al., 2000). However, the immunopharmacological role that selective and nonselective inhibition of PDE isoenzymes plays in regulating the nuclear translocation and activation of NF-κB is not well characterized and thereby remains to be identified in the alveolar epithelium.
Therefore, the aim of the present investigation targeted a dual analytical assessment of PDE inhibition. First, a determination was made of the interference of selective phosphodiesterase isoenzymes in regulating the phosphorylation, degradation, and accumulation of IκB-α within the cytosolic compartment; and second, an evaluation was made of the role that those isoenzymes play in determining the nuclear translocation of selective NF-κB Rel subunits, thereby interfering with the activation of NF-κB, a transcriptional activity involved in regulating genes encoding cytokines and the progression and evolution of inflammation.
Materials and Methods
All experimental procedures involving the use of live animals were reviewed and approved under the Animals Act legislation, 1986 (United Kingdom). Unless indicated otherwise, chemicals/reagents of the highest analytical grade were obtained from Sigma-Aldrich (Dorset, England) and Calbiochem (Nottingham, UK).
Primary Cultures of Alveolar Epithelia.
Fetal alveolar type II epithelial cells were isolated from lungs of rat fetuses on gestation day 19, essentially as described elsewhere (Haddad and Land, 2000a,b; Haddad et al., 2000, 2001a,b,c).
LPS Exposure and Assessment of the Effect of Phosphodiesterase Inhibitors (PDEIs) on NF-κB Translocation/Activation.
The signaling mechanism mediating the effect of selective and nonselective inhibition of PDEs in regulating NF-κB translocation and activation in the alveolar epithelium is not well characterized. Accordingly, we designed a series of experiments to span NF-κB translocation/activation in response to LPS and PDEI treatment. Cells were challenged with LPS (10 μg/ml) independently or in the presence of various PDEIs. Subcellular cytosolic/nuclear extracts (24 h) were subsequently prepared, followed by Western analysis and electrophoretic mobility gel shift assay, essentially as described previously (Haddad and Land, 2000a; Haddad et al., 2000). Briefly, cytosolic/nuclear extracts were prepared from monolayer filters washed twice in 5 ml of ice-cold, pre-equilibrated phosphate-buffered saline and cells (1–2 × 107) were collected and centrifuged at 420g for 5 min at 4°C. Nuclei were released by resuspending the pellet in 250 μl of buffer A containing 10 mM Tris-HCl, pH 7.8, 10 mM KCl, 2.5 mM NaH2PO4, 1.5 mM MgCl2, 1 mM Na3VO4, 0.5 mM dithiothreitol, 0.4 mM 4-(2-aminoethyl)benzenesulfonyl fluoride-HCl, and 2 μg/ml each of leupeptin, pepstatin A, and aprotinin. The suspension was left in ice for 10 min followed by a 45-s homogenization at a moderate speed. Nuclei were collected by centrifuging the slurry at 4500g for 5 min at 4°C and resuspending in 100 μl of buffer B [buffer A adjusted to 20 mM Tris-HCl, pH 7.8, 420 mM KCl, 20% (v/v) glycerol]. The supernatants thus obtained were termed cytosolic extracts. The nuclei were then lysed at 4°C for 30 min with gentle agitation, the debris cleared by centrifugation at 10,000g for an additional 30 min at 4°C, and the supernatants, termed nuclear extracts, were frozen in liquid nitrogen and stored at −70°C until used. In all cases, protein contents were determined by the Bradford method by using bovine serum albumin as a standard (Haddad and Land, 2000a).
Cytosolic and nuclear proteins (20–25 μg) were resolved over sodium dodecyl sulfate-polyacrylamide gel electrophoresis (7.5%) gels at room temperature, blotted onto nitrocellulose membrane, and nonspecific binding sites were subsequently blocked. Mouse monoclonal IgG1 anti-IκB-α (H-4), IgG2b anti-pIκB-α (B-9), rabbit polyclonal IgG anti-p50 (NLS), anti-p52 (K-27), anti-p65 (RelA; A), anti-p68 (RelB; C-19), and anti-p75 (c-Rel; N) (Santa Cruz Biotechnology, Wiltshire, UK) antibodies were used for primary detection. Anti-rabbit Ig-biotinylated antibody (Amersham plc, Little Chalfont, Buckinghamshire, UK) was used for secondary detection followed by the addition of streptavidin-horseradish peroxidase conjugate and visualized on film by chemiluminescence. β-Actin standard was used as an internal reference for semiquantitative loading in parallel lanes for each variable. Western blots were scanned by NIH MagiScanII and subsequently quantitated by UN-Scan-IT automated digitizing system (version 5.1; 32-bit), and the ratio of the density of the band to that of β-actin was subsequently performed.
Custom deoxyoligonucleotide probe sequences were purchased from Genosys (Cambridge, UK): NF-κB, 5′-AGTTGAGGGGACTTTCCCAGGC-3′ (binding sequence underlined). Gel-purified double-stranded DNA was end-labeled with [γ-32P]ATP (PerkinElmer Life Sciences Ltd., Cambridge, UK). Identical amounts of radioactive probe (1–2 × 104 counts/min) were added to binding reactions containing 1 to 5 μg of fetal alveolar type II nuclear extracts in a final volume of 40 μl in DNA binding buffer (20 mM HEPES, pH 7.9; 1 mM MgCl2; 4% Ficoll). Reaction mixtures were incubated for 30 min at 25°C before separating on nondenaturing 4% polyacrylamide gels at room temperature and subjected to electrophoresis with 1:10 5× Tris-borate-EDTA buffer. A nonspecific competitive polydeoxyinosinic-deoxycytidylic acid [poly(dI-dC)] (Amersham plc) was added to reaction mixtures after addition of labeled probe. Gels were transferred to ion-exchange chromatography paper, vacuum dried, and then electronically visualized on a Packard Instant PhosphorImager (Packard BioScience Ltd., Berkshire, UK). Specific quantitation of the corresponding DNA gel shift bands was performed with phosphorimaging (Haddad and Land, 2000a,b; Haddad et al., 2000, 2001a,b).
Statistical Analysis and Data Presentation.
Data are the means and the error bars the S.E.M. of at least three independent cell cultures. Statistical evaluation was performed by one-way analysis of variance, followed by post hoc Tukey's test, and the a priori level of significance at 95% confidence level was considered atP ≤ 0.05.
Results
Involvement of Selective Phosphodiesterase Isoenzymes in Regulating IκB-α Signaling.
In a previous study, we have reported a detailed account of IκB-α signaling in response to exogenous LPS, derived from Escherichia coli (Haddad et al., 2001b). As shown in Fig. 1A, LPS (10 μg/ml; 24 h) mediated the degradation of IκB-α within the cytosolic compartment. Coincubation of cells with LPS and PDEIs differentially regulated LPS-mediated degradation of IκB-α (Fig. 1). The effect of 8-methoxymethyl-IBMX (PDEI1) on IκB-α abundance is shown in Fig. 1A. 8-Methoxymethyl-IBMX had no effect on LPS-dependent degradation of IκB-α at 1 and 10 μM, but reversed the effect of LPS at 100 μM, thereby allowing its cytosolic accumulation (Fig.1A). The effect of 5-amino-(3,4′-bipyridin)-6[1H]-one (amrinone; PDEI3) on IκB-α abundance is displayed in Fig. 1A. In contrast to PDEI1, amrinone reversed the degradation effect of LPS at all doses used in this study, thereby allowing the accumulation of IκB-α in the cytosol (Fig. 1A). In comparison with either PDEI1 and 3,4-[3-(cyclopentyloxy)-4-methoxy-phenyl]-2-pyrrolidinone (rolipram) (PDEI4) partially reversed the effect of LPS on IκB-α abundance, allowing its accumulation but to a lesser extent than the effect of amrinone (Fig. 1A). The effect of MBMQ (PDEI5) on IκB-α abundance is displayed in Fig. 1B. MBMQ did not affect or reverse the effect of LPS at all doses (Fig. 1B). The role of 1,4- dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo[4,5-d]pyrimi dine-7-one (zaprinast) (PDEI5/6/9) in regulating LPS-mediated IκB-α abundance is shown in Fig. 1B. Zaprinast partially reduced LPS-induced IκB-α degradation at 100 μM (Fig. 1B). The effect of pentoxifylline (nonselective PDEI) on IκB-α abundance is displayed in Fig. 1B. Pentoxifylline partially restored IκB-α abundance, especially at 1 and 10 μM, but not at 100 μM (Fig. 1B). Histogram analysis of the effect of selective PDE inhibition on IκB-α abundance is shown in Fig. 2A. Analysis of the half-maximal (50%) excitatory concentration (EC50) of selective and nonselective phosphodiesterase inhibitors on IκB-α abundance/degradation regulated by LPS (10 μg/ml; 24 h) is given in Table 1.
The role of PDE inhibition in regulating the phosphorylation of IκB-α, the major cytosolic inhibitor of NF-κB (Baldwin, 2001;Haddad et al., 2001b), is not well characterized in the alveolar epithelium. Subsequently, after having determined IκB-α abundance within the cytosolic compartment, we aimed at investigating the role that these isoenzymes play in regulating IκB-α phosphorylation. As shown in Fig. 1C, 8-methoxymethyl-IBMX up-regulated LPS-mediated phosphorylation of IκB-α at 1 μM, but not at higher concentrations, whose effects were similar to that of LPS alone (Fig.1C). The effect of amrinone on IκB-α phosphorylation is displayed in Fig. 1C. Amrinone up-regulated LPS-dependent phosphorylation of IκB-α at the highest dose used (100 μM), but not at lower doses (Fig. 1C). Rolipram suppressed LPS-dependent phosphorylation of IκB-α in a dose-independent manner (Fig. 1C). The effect of MBMQ on IκB-α phosphorylation is shown in Fig. 1D. MBMQ up-regulated IκB-α phosphorylation at 100 μM, with similar effects to LPS at the lower range of the dose-response curve (Fig. 1D). The role of zaprinast in regulating LPS-mediated IκB-α phosphorylation is displayed in Fig. 1D. Zaprinast up-regulated LPS-dependent phosphorylation of IκB-α at all doses (Fig. 1D). The effect of pentoxifylline on IκB-α phosphorylation is shown in Fig. 1D. Pentoxifylline up-regulated LPS-mediated phosphorylation of IκB-α at the lowest dose (1 μM), but suppressed this effect at higher doses (Fig. 1D). Histogram analysis of the effect of selective PDE inhibition on IκB-α phosphorylation is shown in Fig. 2B. Analysis of the half-maximal (50%) excitatory and inhibitory concentrations (EC50/IC50) of selective and nonselective phosphodiesterase inhibitors on IκB-α phosphorylation regulated by LPS (10 μg/ml; 24 h) is given in Table 1.
Role of Phosphodiesterase Isoenzyme Inhibition in Regulating Nuclear Translocation of Selective NF-κB RelSubunits.
Although LPS up-regulated the nuclear translocation of NF-κB1 (p50), RelA (p65), RelB (p68), and c-Rel (p75), it had no apparent effect on NF-κB2(p52). 8-Methoxymethyl-IBMX had no inhibitory effect on LPS-mediated translocation of p50, p65, p68, and p75, as shown in Fig.3A. Similar to the effect of 8-methoxymethyl-IBMX, amrinone did not suppress LPS-mediated NF-κB subunit translocation (Fig. 3B). As shown in Fig. 3C, rolipram did not inhibit the translocation of NF-κB subunits. The housekeeping gene protein product β-actin was used as an internal reference for semiquantitative loading per lane (Fig. 3). The effect of MBMQ on NF-κB subunit translocation is displayed in Fig.4A, where there was an inhibitory effect at doses ≥1 μM (p50), ≥10 μM (p65), ≥1 μM (p68), and ≥10 μM (p75). As shown in Fig. 4B, zaprinast blockaded LPS-mediated NF-κB translocation of p50 (≥10 μM), p65 (≥1 μM), p68 (≥1 μM), and p75 (≥10 μM). Pentoxifylline reduced the nuclear localization of p50 (≥1 μM), p65 (≥1 μM), p68 (≥1 μM), and p75 (≥1 μM), as shown in Fig. 4C. The housekeeping gene protein product β-actin was used as an internal reference for semiquantitative loading per lane (Fig. 4). Analysis of the half-maximal (50%) excitatory and inhibitory concentrations (EC50/IC50) of selective and nonselective phosphodiesterase inhibitors on NF-κB subunit nuclear abundance regulated by LPS (10 μg/ml; 24 h) is given in Table 2.
Effect of LPS on NF-κB DNA-Binding Activity: Time-Response Analysis.
As shown in Fig. 5A, incubation of epithelial cells with LPS (10 μg/ml) induced, in a time-dependent manner, NF-κB activation. The nuclear activity of NF-κB in response to LPS emerged significantly as early as 2 h postaddition to monolayers, and continued to increase in an exponential manner to maximize at 16- to 24-h time point (Fig. 5A). LPS-mediated activity of NF-κB thereafter subsided beyond the 24-h time point, although it remained significantly different from control (no LPS) until 72 h, when it became insignificant at 96 h (Fig. 5A). Histogram analysis of the corresponding gel-shifted bands is given in Fig. 5B.
Effect of Phosphodiesterase Isoenzyme Inhibition on Nuclear Activation of NF-κB.
In association with the differential regulation of selective PDE inhibition on NF-κB subunit translocation, PDEI revealed a novel role in regulating LPS-dependent NF-κB activation by interfering with the binding to specific κB moieties. As shown in Fig. 6A, 8-methoxymethyl-IBMX augmented LPS-induced NF-κB activation at 1 and 10 μM, with no apparent effect at 100 μM, the effect of which was similar to LPS alone. Histogram analysis of the corresponding gel-shifted bands with 8-methoxymethyl-IBMX is given in Fig. 8A. Although amrinone at doses 1 and 10 μM behaved in a similar manner to LPS, it up-regulated the effect of LPS at 100 μM (Fig. 6B). Histogram analysis of the corresponding gel-shifted bands with amrinone is given in Fig. 8B. Rolipram up-regulated LPS-mediated activation of NF-κB in a dose-dependent manner (Fig. 6C). Histogram analysis of the corresponding gel-shifted bands with rolipram is given in Fig. 8C. The effect of MBMQ on NF-κB activation is displayed in Fig.7A, where its inhibitory effects are evident at doses ≥10 μM. Histogram analysis of the corresponding gel-shifted bands with MBMQ is given in Fig.8D. Similarly, zaprinast suppressed the nuclear activation of NF-κB at doses ≥10 μM (Fig. 7B). Histogram analysis of the corresponding gel-shifted bands with zaprinast is given in Fig. 8E. The effect of nonselective inhibition of PDE by pentoxifylline is shown in Fig. 7C, where there was a dose-dependent inhibition. Histogram analysis of the corresponding gel-shifted bands with pentoxifylline is shown in Fig. 8F. Analysis of the half-maximal (50%) excitatory and inhibitory concentrations (EC50/IC50) of selective and nonselective phosphodiesterase inhibitors on NF-κB activation regulated by LPS (10 μg/ml; 24 h) is given in Table 2.
Discussion
To accommodate an ever-changing microenvironment, cells adjust the pattern of gene expression by adaptive regulation of a host of transcription factors, which bind their respective cognate sites in the regulatory elements of targeted genes (Makarov, 2000; Baldwin, 2001;Tak and Firestein, 2001; Yamamoto and Gaynor, 2001). NF-κB comprises the Rel family of inducible transcription factors that are key mediators in regulating the progression of the inflammatory process (Yamamoto and Gaynor, 2001). Therefore, activation/regulation of the NF-κB/Rel transcription family, via nuclear translocation of cytoplasmic entities and complexes, plays a central role in the evolution of inflammation through regulation of genes essentially involved in encoding proinflammatory cytokines and other inflammatory mediators (Baldwin, 1996, 2001; Tak and Firestein, 2001). The NF-κB/Rel family includes five members: NF-κB1 (p50/p105 {p50 precursor}), NF-κB2 [p52/p100 (p52 precursor)], RelA (p65), RelB (p68) and c-Rel (p75) (Tak and Firestein, 2001). Despite the ability of most Rel members (with the exception of p68) to homodimerize, as well as form heterodimers, with each other, the most prevalent activated form of NF-κB is the heterodimer p50-p65, which possesses the transactivity domains necessary for gene regulation (Baldwin, 1996; Makarov, 2000;Baldwin, 2001). The NF-κB members contain a Rel homology domain, which is responsible for dimer formation, nuclear translocation, sequence-specific consensus DNA recognition, and interaction with IκB, the cytosolic inhibitors of NF-κB (Baldwin 2001; Tak and Firestein, 2001). In unstimulated cells, NF-κB resides in the cytoplasm as an inactive NF-κB/IκB complex, a mechanism that hinders the recognition of the NLS by the nuclear import machinery, thereby retaining the NF-κB complex within the cytosol (Baldwin, 1996, 2001).
Signals emanating from membrane receptors, such as those for interleukin-1 and tumor necrosis factor-α, activate members of the mitogen-activated protein kinase kinase kinase-related family, including NF-κB inducing kinase and mitogen-activated protein kinase kinase kinase1, both of which are involved in the activation of IκB kinases, IKK1 and IKK2, components of the IKK signalsome (Mercurio and Manning 1999; Zandi et al., 1997; Makarov, 2000). These kinases phosphorylate members of the IκB family, including IκB-α, the major cytosolic inhibitor of NF-κB (Baldwin, 2001;Haddad et al., 2001b), at specific serines within their amino termini, thereby leading to site-specific ubiquitination and degradation by the proteasome. This sequential trajectory culminating in the inducible degradation of IκB, which occurs through consecutive steps of phosphorylation and ubiquitination, allows freeing of the NF-κB complex, which translocates to the nucleus to bind specific κB moieties and initiate gene transcription (Makarov, 2000; Baldwin, 2001). The immunoregulatory potential aimed at targeting the NF-κB signaling pathway, therefore, remains of particular interest. Because NF-κB regulates host inflammatory and immune responses by increasing the expression of specific genes and enzymes whose products contribute to the pathogenesis of the inflammatory process (Makarov, 2000;Yamamoto and Gaynor, 2001), selective modulation of this transcription factor bears a typical therapeutic approach for the control and regulation of inflammatory-associated diseases. Unfortunately, due to convergence of more than one mechanism upon the onset and progression of the inflammatory process, which regulates NF-κB signaling, it has been extremely difficult to solely target this pathway without affecting other cellular functions. Within this context, the anti-inflammatory immunoregulatory role that phosphodiesterase inhibition plays in regulating this pathway is not well understood or characterized. Therefore, the major aim of the present investigation was to shed light on the role that selective phosphodiesterases play in regulating IκB-α/NF-κB signaling, thereby showing for the first time that PDE inhibition differentially and dually regulates this transduction pathway, bearing consequences for the therapeutic treatment of inflammatory disease involving NF-κB and regulated by the respiratory epithelium (Makarov, 2000; Perkins, 2000; Haddad et al., 2001c,d; Yamamoto and Gaynor, 2001).
Although the inflammatory signals mediated by LPS are recognized in other systems and cell models, the role of LPS-mediated signaling and its modulation by PDE isoenzymes in the alveolar epithelium is not well characterized. Administration of LPS differentially regulated NF-κB nuclear subunit translocation. Despite the observation that LPS has no influence on the unit composition of p52, its stimulatory effect on p50, p65, p68, and p75 is evidently prominent. Besides, the promoters of genes encoding cytokines contain multiple cis-acting motifs, including those that bind specific subunits (i.e., p50-p65) of such transcription factors as NF-κB (Makarov, 2000; Baldwin, 2001;Tak and Firestein, 2001). Furthermore, the release of free NF-κB upon extracellular stimulation due to IκB phosphorylation and degradation, leads to DNA binding to initiate transcription of related genes, including immunoreceptors, cytokines, and, interestingly, its own inhibitor, IκB (Mercurio et al., 1997; Baldwin, 2001; Haddad et al., 2001b). Two unique features of the NF-κB/IκB complex system are deduced from its feedback regulation. The transcriptional activation of NF-κB triggers the synthesis of IκB, and NF-κB-activated transcription is maintained by continuous degradation of IκB, which is sustained by an extracellular stimulus (Perkins, 2000; Baldwin, 2001; Haddad et al., 2001b). Thus, the expression of IκB parallels both NF-κB activity and the duration of the activating extracellular stimulation, suggesting that this temporal parallelism between IκB accumulation/degradation and an effective external stimulation is a mechanism allowing dual, biphasic, regulation of NF-κB within the alveolar space.
The novel interference of specific PDE isoenzyme inhibition in regulating IκB-α phosphorylation/degradation, translocation of selective NF-κB subunits, and the activation of this transcription factor remains of particular interest. Phosphodiesterase regulation of IκB-α/NF-κB signaling pathway, however, is not well understood and remains to be elucidated. Coward et al. (1998), for example, reported that nonselective PDE inhibition possesses an anti-inflammatory activity via suppression of NF-κB, bearing consequences for the treatment of asthmatic patients. Furthermore, pentoxifylline, a nonspecific methylxanthine-derived PDE inhibitor, selectively targeted the c-rel (p75) NF-κB subunit, with variable and inconsistent effect on RelA (p65), in the treatment of T-cell-dependent diseases (Wang et al., 1997), an observation correlating with another investigation (Lee et al., 1997). Alternatively, it was demonstrated that the PKAc, but not the protein kinase A regulatory subunit, binds IκB proteins and is associated with the NF-κB-IκB complex (Zhong et al., 1997). The authors concluded that PKAc interacts with IκB-α and IκB-β through sequences from the N terminus of the protein, and that this interaction inhibits the catalytic activity of PKAc. Of note, the observation that stimulation of cells with inducers of NF-κB activity, such as LPS, agents that do not elevate intracellular cAMP, led to degradation of IκB proteins and consequent activation of IκB-bound PKAc (Zhong et al., 1997). To the best of our knowledge, this is the first report that has given a detailed account of the role of selective and nonselective PDE interference in regulating IκB-α/NF-κB signaling. The differential regulation of IκB-α phosphorylation, in particular, implicated a PDE-sensitive upstream kinase. However, from the present data alone it cannot be concluded which of the upstream kinases are directly regulated by selective regulation of PDE isoenzymes. Nevertheless, because the IKK signalsome (Mercurio et al., 1997; Zandi et al., 1997; Makarov, 2000) is involved in regulating IκB-α phosphorylation in response to various stimuli, including LPS, it remains tempting to suggest that this complex is likely to form a target of the selective regulation by PDEs. Furthermore, whether this differential regulation of IκB-α phosphorylation/degradation is cAMP/cGMP-dependent cannot be confirmed based on the aforementioned observations alone; however, because PDE inhibitors are involved in regulating the dynamic equilibrium of these cyclic nucleotides, the possibility that LPS-mediated IκB-α phosphorylation is cAMP/cGMP-sensitive cannot be excluded, an observation correlating with the transcriptional activity of either nucleotide (Montminy, 1997; Zhong et al., 1997; Ma et al., 1999).
In association with targeting the IκB-α signaling pathway, we observed differential regulation of NF-κB translocation and activation. Despite the observation that selective inhibition of PDEs 1, 3, and 4 exhibited no inhibitory effect on LPS-mediated translocation of NF-κB subunits, blockading the activity of 5, 6, and 9 differentially attenuated, and to relatively variable degree, LPS-dependent translocation of these subunits. Because the latter isoenzymes are directly involved in cGMP signaling, it is possible that cAMP-mediated signaling tends to up-regulate NF-κB nuclear accumulation, whereas the former pathway mediates an inhibitory effect, thereby retarding the nuclear localization of selective subunits. This discrepancy between the modes of action of either pathway suggested that there is a line of demarcation highlighting the divergence of these signaling mechanisms, especially on the bifurcation of interest that substantially resides within and/or above the IκB/NF-κB complex. Substantially working with effectiveness as competitive as selective inhibition of PDEs 5, 6, and 9, pentoxifylline reduced LPS-mediated NF-κB translocation, suggesting the involvement of a common signaling pathway converging on NF-κB.
Analysis of this differential regulation of NF-κB subunit translocation revealed the involvement of a novel biphasic pathway mediating the interference in NF-κB activation. Although selective inhibition of PDEs 1, 3, and 4 had a mild tendency to up-regulate the activation of this transcription factor, ostensibly due to accumulation of intracellular cAMP, selective inhibition of PDEs 5, 6, and 9 (↑ cGMP), along with pentoxifylline, negatively regulated LPS-mediated NF-κB activation. This phenomenon is rather reinforced by the observation that the molecular mechanism of inhibition by cAMP was found to correlate with NF-κB, in particular, the RelA component of the complex (Neuman et al., 1995). Based on their chemical structures, PDE inhibitors (1, 3, and 4 versus 5, 6, and 9) tend to elevate cAMP/cGMP, respectively; however, it may also be true that in some situations this may not be the only mode of action. In preference to this understanding, some of the effects of PDE inhibition, for example, may be implicated in regulating the process of cellular differentiation, an effect not mimicked by cAMP (Yang et al., 1995). Furthermore, exogenous addition of TNF-α in the presence of rolipram, purported to elevate intracellular cAMP, restored NF-κB activation but not that of NFAT (Navarro et al., 1998). Of note, a possible relationship of pentoxifylline to Ca2+mobilization has been declared because optimal c-Rel induction has been shown to require the dual signal of phorbol-12-myristate-13-acetate and ionomycin, where it was inferred that this nonselective PDE inhibitor would blockade c-Rel induction by attenuating a component of the calcium response (Yang et al., 1995). From the aforementioned mechanisms reported, it is not clear, however, whether PDE inhibition is involved in regulating selective NF-κB subunits in correlation with the suppression or augmentation of transcriptional activation. This investigation has created a basis for the hypothesis claiming that selective PDE blockade differentially regulate NF-κB translocation/activation, with detailed mechanics of action on certain subunits, where we have shown that not only c-Rel or RelA are targets for the mode of action of PDEs but also other components of the complex along with the machinery of IκB signaling that converge on regulating the NF-κB pathway. Despite the selective regulation of specific NF-κB subunit translocation/activation by PDE isoenzymes reported in this study, whether the mode of action is solely cAMP/cGMP-sensitive cannot be inferred. However, previous studies in our laboratory have demonstrated that cyclic nucleotides and their mimetics (forskolin, dibutyryl cAMP, and dibutyryl cGMP) have differentially regulated proinflammatory cytokine biosynthesis, a phenomenon shown to be correlated with the selective interference of NF-κB translocation and activation (J. J. Haddad, N. E. Saadé, B. Safieh-Garabedian, and S. C. Land, unpublished observations).
We herein report a novel immunopharmacological potential of selective and nonselective PDE inhibition in the process of regulating the IκB-α/NF-κB signaling transduction pathway. The results could be highlighted as follows: 1) PDE blockade at the level of the diverging cAMP/cGMP pathways differentially regulated the phosphorylation and degradation of IκB-α, the major cytosolic inhibitor of NF-κB; 2) inhibition of PDEs 1, 3, and 4 exhibited a tendency to augment the process of selective NF-κB subunit translocation, an effect associated with up-regulating transcriptional activity; and 3) blockading the activity of PDEs 5, 6, and 9 negatively attenuated LPS-mediated NF-κB translocation/activation. It is concluded that selective and nonselective interference with the control of the dynamic equilibrium of cyclic nucleotides via PDE isoenzyme regulation represents an immunopharmacological approach targeting the IκB-α/NF-κB complex and the downstream signaling pathway, thereby conferring a novel mode of action for targeting a transcriptional activity notoriously implicated in regulating the progression of the inflammatory process and its contraction in disease.
Footnotes
-
This study was supported by grants from Medical Research Council, Anonymous Trust, and Tenovus-Scotland (to S.C.L.), and R.L. allocated grants for supporting this research. J.J.H. holds the Georges John Livanos prize (London). Parts of this work were presented at Experimental Biology meeting; 2001 March 31–April 4; Orlando, FL.
- Abbreviations:
- NF-κB
- nuclear factor-κB
- IκB
- inhibitory-κB
- LPS
- lipopolysaccharide-endotoxin
- NLS
- nuclear localization sequence
- PDE
- phosphodiesterase
- PKAc
- catalytic subunit of protein kinase A
- PDEI
- phosphodiesterase inhibitor
- MBMQ
- 4-{[3′,4′-(methylenedioxy)benzyl]amino}-6-methoxyquinazoline
- 8-methoxymethyl-IBMX
- 8-methoxymethyl-3-isobutyl-1-methylxanthine
- IKK
- IκB kinase
- NFAT
- nuclear factor of activated T cells
- Received July 27, 2001.
- Accepted October 19, 2001.
- The American Society for Pharmacology and Experimental Therapeutics